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Abstract
Background: Dendritic cells (DC) pulsed with tumor-derived antigenic material have widely been
used in antitumor vaccination protocols. However, the optimal strategy of DC loading has not yet
been established. Our aim was to define requirements of optimal DC vaccines in terms of in vivo
protection in a murine B-cell lymphoma model.
Methods: We compare various loading reagents including whole parental and modified tumor
cells and a single tumor-specific antigen, namely the lymphoma idiotype (Id). Bone marrow-derived
DC were pulsed in vitro and used for therapy of established A20 lymphomas.
Results: We show that a vaccine with superior antitumor efficacy can be generated when DC are
loaded with whole modified tumor cells which provide both (i) antigenic polyvalency and (ii)
receptor-mediated antigen internalization. Uptake of cellular material was greatly enhanced when
the tumor cells used for DC pulsing were engineered to express an anti-Fc receptor
immunoglobulin specificity. Upon transfer of these DC, established tumor burdens were eradicated
in 50% of mice. By contrast, pulsing DC with unmodified lymphoma cells or with the lymphoma Id,
even when it was endowed with the anti-Fc receptor binding arm, was far less effective. A specific
humoral anti-Id response could be detected, particularly following delivery of Id protein-pulsed DC,
but it was not predictive of tumor protection. Instead a T-cell response was pivotal for successful
tumor protection. Interaction of the transferred DC with CD8+ T lymphocytes seemed to play a
role for induction of the immune response but was dispensable when DC had received an
additional maturation stimulus.
Conclusion: Our analyses show that the advantages of specific antigen redirection and antigenic
polyvalency can be combined to generate DC-based vaccines with superior antitumor efficacy. This
mouse model may provide information for the standardization of DC-based vaccination protocols.
Background
Dendritic cells (DC) are professional antigen-presenting
cells (APC) that are effective at presenting immunogenic
peptides in the context of major histocompatibility com-
plex (MHC) molecules and providing the costimulatory
signals necessary for efficient T-cell stimulation [1-3]. DC-
based vaccination against tumor-associated antigens
(TAA) has received much interest in experimental cancer
therapy. To allow TAA to be efficiently presented to T cells,
DC were pulsed with proteins or synthetic peptides [4,5]
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or transduced with viral vectors [6,7]. In murine tumor
models, DC loaded with single TAA induced effective anti-
tumor responses [5,8]. However, vaccination with a single
antigen (Ag) may be less efficient than immunization
against a panel of Ag because in the latter setting, selection
of Ag loss mutants is less likely to occur and even still uni-
dentified TAA can be included [9-13]. DC were therefore
used in tumor vaccination protocols that were pulsed with
whole tumor cell lysates [14]. On the other hand, it was
shown that loading of more than one epitope on APC
inhibits T-cell priming [15] due to competition of pep-
tides for MHC molecules and of T cells for access to APC.
The consequences of this finding for antitumor immuni-
zation in vivo, however, have not yet been addressed and
the optimal DC loading strategy still remains to be
defined.
A critical step in antitumor immunization is the engulf-
ment of TAA by APC. It was shown that this is most effi-
ciently mediated by adsorptive endocytosis. Thus,
antibody- (Ab-) dependent redirection of Ag to endocy-
tosing Fc receptors FcγRI and FcγRII expressed by APC
gave rise to potent immune responses [16-25]. Induction
of Ag-specific humoral responses in vivo was even possible
against weak immunogens such as the immunoglobulin
(Ig) idiotype (Id) of B-cell lymphomas [9,12,25] which is
an absolutely tumor-specific Ag. However, this immunity
was not capable of conferring complete tumor protection
in some mouse models in vivo [9,12]. As immunization
against a panel of tumor-derived Ag turned out to be nec-
essary for successful tumor rejection in different tumor
models [9-13,26], we investigated exogenous loading of
DC that relies on Ag targeting to FcγR but nevertheless can
provide antigenic polyvalency. Both antigenic polyva-
lency and receptor-mediated Ag internalization was
achieved by pulsing DC with whole tumor cells that were
modified to express an FcγR specificity.
Tumor rejection in vivo is the most rigorous readout sys-
tem for antitumor immunity. A systematic comparison
revealed that in terms of tumor therapy, whole anti-FcγR-
expressing tumor cells were most suitable for DC loading
not only in comparison to unmodified lymphoma cells
but also to soluble Id proteins even when these were engi-
neered to be redirected to FcγR. This system showed that a
possible competition of multiple epitopes as described
elsewhere [15] plays no role for successful tumor rejection
in vivo.
Methods
Cell culture
All cells were cultured in RPMI 1640 medium supple-
mented with 5% fetal calf serum, 2 mM glutamine, non-
essential amino acids, 50 µM 2-mercaptoethanol and
antibiotics at 37°C in a humidified 5% CO2 atmosphere.
The trioma cell line BiV was generated by fusing A20 cells
[27] to the rat anti-mouse FcγR hybridoma 2.4G2 as
described earlier [9]. 5C12 is an A20 variant that was
genetically engineered to express the Id as an Ig/GM-CSF
fusion protein [10]. DC were prepared by culturing bone
marrow precursors from BALB/c wildtype or β2m-/- mice in
standard medium in the presence of 100 ng/ml recom-
binant murine granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) [26]. Medium was replaced every two
days. On day 8, DC were pulsed for 12 hours with A20 or
BiV cells (irradiated at 100 Gy and 20 Gy, respectively; cell
ratio 1:1) or with 100 to 300 µg/ml A20 Id, BiV het-
erodimeric Ig protein or with 5C12 fusion protein. The
latter was used for differentiation of DC from bone mar-
row precursors as well as for the loading step. The proteins
were purified from culture supernatants using protein A
chromatography as described elsewhere [9,10,28]. If not
otherwise indicated, DC were then exposed to 1 µg/ml
lipopolysaccharide (LPS) for maturation. DC were exten-
sively characterized by fluorescence-activated cell sorting
(FACS) using monoclonal Ab (mAb) against MHC class I,
MHC class II, CD80, CD86 and CD40. Prior to injection
into mice, DC were separated from the loading proteins
by washing and from the cellular Ag sources by negative
immunomagnetic separation (Miltenyi Biotec, Bergisch-
Gladbach, Germany) using the anti-Id mAb 6C10 [10].
Control experiments showed that BiV cells alone which
were depleted by this separation step had no therapeutic
effect.
Cell uptake assay and confocal microscopy
BiV and A20 cells were irradiated or killed by one freeze-
thaw cycle and labelled with 10 µM per 107 cells of carbox-
yfluorescein diacetate succinimidyl ester (CFDA; Invitro-
gen, Karlsruhe, Germany) as recommended by the
manufacturer. Immature DC (iDC) were harvested on day
8 and coincubated with the CFDA-labelled A20 or BiV
cells for 1 or 4 hr at 37°C or 4°C. Then DC were labelled
with PE-conjugated anti-CD11c or anti-CD80 mAb
(Pharmingen, Heidelberg, Germany) and Cy5-conjugated
anti-MHC class II (HB3, ATCC, Manassas, USA). Uptake
of CFDA-labelled A20 or BiV cells was monitored using
multicolour flow cytometry (CyAn-ADP, Dakocytoma-
tion, Hamburg, Germany) by gating of CD11c/MHCII
double-positive DC. Dead cells were excluded using pro-
pidium iodide vital staining.
For confocal microscopy, DC that had ingested CFDA-
labelled cells as described above were counterstained with
TRITC-conjugated anti-CD11c. The DC were then
attached to poly-L-lysin-coated slides as described previ-
ously [29], fixed for 20 min. using 2% paraformaldehyde
and processed on a Leica TCS SP2 confocal microscope.
The cell uptake and microscopic studies were performed
three to five times.Journal of Translational Medicine 2007, 5:16 http://www.translational-medicine.com/content/5/1/16
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Animal experiments
BALB/c wildtype and β2m-/- mice were purchased from
Bommice (Ry, Denmark) and The Jackson Laboratories
(Bar Harbor, USA), respectively. All animal experiments
were approved by the Regierung von Oberbayern. Groups of
6 female mice received a lethal tumor challenge i.v. (7 to
8 × 105 A20 cells) at day 1. Therapy was done by s.c. injec-
tion of 5 × 105 DC at day 5 and again at day 11. To assess
longterm memory, surviving animals received an A20
rechallenge about 100 days later. Mice were killed when
first signs of tumor growth appeared. Depletion of T-cell
subsets was done by injecting mAb RmCD4-2 or RmCD8-
2 i.p. starting 4 days before therapy [9]. To test for
humoral immune responses mice were bled before begin-
ning of the experiment and three weeks after therapy. All
animal experiments were performed at least twice. In the
figures, typical results are shown. Statistical analyses were
done using the logrank test. Survival curves are shown
until day 200 although the animals were followed at least
for 1 1/2 years. Generally, mice surviving day 100
remained tumor-free life-long.
T-cell proliferation assay and test for humoral anti-Id 
immunity
After pulsing and maturation, DC were irradiated at 20 Gy
and cocultivated with syngeneic T cells at different T cell/
DC ratios in 96-well round-bottom plates. 5 days later, T
cells were pulsed with 1 µCi 3H-thymidine. Cells were har-
vested after 20 hours and incorporated radioactivity was
determined in a liquid scintillation counter. Proliferation
indices were calculated by normalizing the radioactivity
incorporated in T cells to the background levels without T
cells. Mean indices and standard deviations were calcu-
lated from three experiments.
Anti-Id responses in mouse sera were determined by
enzyme-linked immunosorbent assay (ELISA) exactly as
described previously [9,10]. In brief, Ab in mouse sera
were captured by the A20 Ig purified from culture super-
natants and detected by polyclonal anti-mouse Fc Ab
which was preabsorbed against mouse IgG2a. Results
were expressed as those reciprocal Ab titres that gave two-
fold extinction above background.
Results and Discussion
Loading of DC in vitro
The murine A20 lymphoma was converted to the trioma
cell line BiV by fusion with a xenogeneic (rat) hybridoma
producing an anti-mouse FcγR Ab. The trioma cells con-
tained most if not all genetic material derived from A20
[12] and expressed the anti-APC specificity as secreted and
as membrane-bound Ab [9,12]. It is established that tar-
geting of soluble Ag to FcγR expressed on APC induces
potent immune responses. To show that even a variety of
TAA can be efficiently redirected to APC in vitro when
whole cells are endowed with the anti-FcγR specificity,
iDC were cultured with irradiated CFDA-labelled A20 or
BiV cells. After one hour of coincubation at 4°C or at
37°C, the fluorescence of the DC was measured by flow
cytometry. While the average uptake of A20 cells was only
1.5-fold enhanced at 37°C in comparison to 4°C (Fig.
1a), the internalization of BiV cells was increased 8.5-fold
(Fig. 1b), in some experiments up to 12-fold. Identical
results were obtained after 1 hour and after 4 hours of
coincubation. To show that the data reflect ingestion of
the cells by the DC and not only aggregation of cells or
membrane fragments to the surface of DC, confocal
microscopy was performed. As exemplarily shown in Fig.
2c, labelled fragments were indeed detected intracellularly
as can be seen by overlay of CD11c (Fig. 2a) and CFDA
(Fig. 2b) staining.
We then tested the consequences of DC loading for stim-
ulating syngeneic T lymphocytes in proliferation assays
(Fig. 3). The stimulating potential of DC that were pulsed
with irradiated A20 cells or with the purified A20 Ig did
not differ from unpulsed DC. To assess the effect of FcγR-
targeting of the A20 Ig we used a construct which com-
bines the murine lymphoma Id with the rat anti-APC
binding arm in the form of a heterodimeric Ig. Due to
preferential pairing between Ig heavy and light chains of
corresponding specificities observed when the parental
antibodies are of different species origin [28], the BiV cells
expressed this "bispecific Ab" at high yield and also
secreted it into the culture supernatant [9]. In contrast to
the unmodified purified Id protein, the soluble A20/anti-
APC Ig heterodimer when loaded to DC gave rise to a clear
T-cell response which might be directed against the A20 Id
but also to xenogeneic determinants derived from the rat
Ig. Apart from enhanced Ag engulfment mediated by FcR-
targeting, a higher stimulatory capacity of FcR-stimulated
DC may promote the effect, although alterations of matu-
ration markers were not seen after incubation of DC with
anti-FcR. When whole irradiated BiV cells were used for
DC pulsing, the T-cell response was most pronounced.
The additional increase as compared to the heterodimeric
Ig protein may be explained by the antigenic polyvalency
provided by whole cells. T cells will be directed against
multiple epitopes derived from the tumor cells as well as
against a variety of xenogeneic peptides derived from the
fusion partner of the trioma. Of course, it is not clear from
the stimulation experiments what the extent of an antitu-
mor and the xenogeneic response may be, but in vivo
experiments clearly showed that there was indeed a
tumor-reactive component (vide infra). As predicted,
blocking FcγR by the soluble anti-FcγR mAb 2.4G2 during
cocultivation reduced the T-cell-stimulating activity of the
DC (Fig. 3). The T-cell proliferation remaining after block-
ing with 2.4G2 could be related to receptor-independent
Ag uptake and xeno-reactivity, but it is also possible thatJournal of Translational Medicine 2007, 5:16 http://www.translational-medicine.com/content/5/1/16
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Incorporation of cellular material derived from unmodified lymphoma cells or from trioma cells by DC Figure 1
Incorporation of cellular material derived from unmodified lymphoma cells or from trioma cells by DC. A20 (a) 
or BiV cells (b) were labelled with CFDA and coincubated for 1 hour with iDC at 4°C or 37°C. CFDA fluorescence of viable, 
CD11c and MHC class II double-positive DC was measured by flow cytometry. Typical result from 5 experiments using BiV 
and 3 experiments using A20 cells. The average uptake of A20 cells was 1.5-fold increased at 37°C in comparison to 4°C 
(standard deviation = 0.2), the internalization of BiV cells was increased 8.5-fold in an average (s = 1.2).
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Confocal microscopy of DC after internalization of CFDA-labelled A20 cells Figure 2
Confocal microscopy of DC after internalization of CFDA-labelled A20 cells. Uptake of cells was performed for 1 hr 
at 37°C. (a) DC visualized with TRITC-conjugated anti-CD11c Ab (red). (b) CFDA fluorescence. (c) Overlay of TRITC and 
CFDA fluorescence. Typical result from 3 independent experiments.Journal of Translational Medicine 2007, 5:16 http://www.translational-medicine.com/content/5/1/16
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mAb blocking was not complete. In summary, the supe-
rior T-cell-activating effect exerted by trioma cell-pulsed
DC may be due (i) to the enhanced FcγR-mediated Ag
internalization, (ii) to the antigenic polyvalency, (iii) to
the xenogeneic moiety included in the triomas and (iv)
possibly to an increased stimulatory capacity of FcR-
trigerred DC.
Therapeutic effect of trioma-loaded DC
To examine the in vivo consequences of T-cell activation,
DC that were pulsed with various tumor-derived reagents
were used for the therapy of established A20 burdens in
mice. Whereas DC loaded with unmodified Id had no
therapeutic effect, those DC that were pulsed with the het-
erodimeric Ig derived from BiV were able to confer a mod-
est survival benefit (Fig. 4a). Because GM-CSF receptors
are also thought to mediate Ag internalization, we also
delivered the A20 Id to DC in form of an Ig/GM-CSF
fusion protein. The construct 5C12 which contains GM-
CSF attached to the Fc region of the A20 Ig [10] induced
differentiation of DC (not shown), but those DC whose
GM-CSF receptors were targeted were not able to rescue
mice from tumor growth (Fig. 4a).
We then examined the therapeutic potential of DC that
were pulsed in vitro with the cellular Ag sources. Loading
with irradiated A20 cells was ineffective, while 50% of
tumor-bearing mice were cured upon transfer of BiV cell-
pulsed DC (Fig. 4b). These animals also developed a long-
term memory because they were able to reject a wildtype
tumor rechallenge given about 100 days later (not
shown). Pulsing DC with a mixture of A20 cells and the
soluble heterodimeric Id protein had a similar marginal
effect as the Id protein alone (Fig. 4b). Thus, it is pivotal
that the anti-FcγR specificity be expressed by the cellular
Ag source. The advantage of the cellular vaccine can only
be exploited in combination with its anti-FcγR expression.
The rejection of the wildtype A20 lymphoma in vivo
exactly reflected the hierarchy of T-cell activation observed
in the proliferation assays. Whereas the in vitro data did
not allow to distinguish between tumor-specific and
xeno-reactive T-cell activation mediated by BiV cell-pulsed
DC, the therapy studies demonstrated that, in vivo, T cells
were activated which are indeed tumor- and not only
xeno-reactive. In summary, we assume that a prerequisite
for successful antitumor therapy is the combination of
FcγR redirection and antigenic polyvalency. T cells stimu-
lated by xenogeneic peptides should additionally enhance
the antitumor efficacy by virtue of a bystander effect
[9,12].
Mechanisms of DC-induced tumor immunity
Since the Id is a unique tumor Ag expressed on B-cell lym-
phoma we tested for the presence of humoral anti-Id
responses in mice having received therapy with DC that
were loaded with BiV protein or BiV cells. There were con-
siderably higher anti-Id titres when DC were loaded with
the specific protein (Fig. 5a) although tumor protection
was less efficient. Furthermore, Ab responses in mice that
received BiV cell-pulsed DC did not correlate with the
individual survival times. Thus, the advantage of pulsing
DC with whole trioma cells which is clearly demonstrated
by the survival benefit is not reflected by the Id-specific Ab
titres. In vivo protection may be dependent on other spe-
cificities than the Id or exclusively on a cellular immune
response. Nonetheless, a role of cytotoxic anti-Id Ab for
mediating tumor eradication cannot be completely
excluded.
To elucidate the role of the cellular antitumor response
mice were depleted of T cells before the onset of therapy.
Ablation of CD4+ cells or CD8+ cells totally abrogated the
therapeutic effect of trioma cell-pulsed DC (Fig. 5b). This
indicates that both T-cell subsets are crucial for DC-
induced tumor immunity. The requirement for CD4+ T
lymphocytes may be in accordance with the concept that
exogenous proteins are taken up and processed by DC and
presented to CD4+ cells in association with MHC class II
molecules. Activated CD4+ cells then provide help for effi-
cient generation of CTL. In contrast, intracellular Ag are
thought to be presented by MHC class I molecules to
CD8+ CTL, but it has become clear that exogenous pro-
teins can also be directed to the endogenous presentation
pathway thus leading to CTL induction through cross-
presentation.
To answer the question whether DC whose FcγR are tar-
geted with trioma cells only present immunogenic pep-
tides to CD4+ cells or cross-presentation to CD8+ cells also
plays a role, therapy experiments were repeated using tri-
oma cell-pulsed DC from β2m-deficient mice. When these
DC were transferred in an immature state, therapy failed
(Fig. 5c) whereas iDC from normal mice were effective. As
β2m-deficient DC cannot directly interact with CD8+ T
lymphocytes, we conclude that cross-presentation to
CD8+ cells is necessary for inducing optimal tumor protec-
tion in this setting. In contrast, when β2m-deficient DC
were subjected to a maturation step following pulsing
with trioma cells, the therapeutic effect was not signifi-
cantly different from the effect which was observed using
mDC from wildtype mice. It is conceivable that mDC cir-
cumvent the need of direct contact between transferred
DC and CD8+ T cells because they activate helper cells
more efficiently than their immature counterparts.
Conclusion
Trioma cells are B-cell lymphomas modified to express an
FcγR binding specificity [9]. By targeting whole trioma
cells that harbour potentially all lymphoma-derived Ag
against FcγR-bearing professional APC, this approach hasJournal of Translational Medicine 2007, 5:16 http://www.translational-medicine.com/content/5/1/16
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the potential to overcome the insufficient Ag presentation
by malignant B cells and to induce a polyvalent antitumor
response, as was shown by delivering trioma cells as a cel-
lular vaccine in vivo [9,12,26]. In the present study, we set
out to optimize exogenous pulsing of DC for tumor
immunotherapy in a murine lymphoma model and estab-
lished an ex vivo modification of the trioma approach. DC
for vaccination against B-cell lymphoma were pulsed with
trioma cells thereby combining antigenic polyvalency and
targeting of tumor-derived Ag to FcγR expressed on DC.
Other endocytic receptors like DEC-205 may also be suit-
able target structures for directing Ag to DC [30]. Xenoge-
neic peptides presented by DC which have been pulsed
with trioma cells are likely to further enhance T-cell acti-
vation.
As a model for a single tumor Ag, we included in our anal-
yses the lymphoma Id which has been considered as an
attractive tumor rejection target because it is an absolutely
unique tumor Ag. In vitro studies and clinical investiga-
tions revealed the induction of specific CTL responses by
Id-pulsed DC [31-33]. In the A20 model investigated in
our study, however, DC loaded with Id protein alone,
even in the form of an Id/anti-FcγR heterodimer, exerted
only a marginal therapeutic effect in vivo. This may be
explained by the A20 tumor being a highly aggressive B-
cell lymphoma. The successful therapy of pre-established,
disseminated tumor burdens using trioma cell-based DC
therefore highlights the potency of this approach.
Although Id-specific humoral responses could be detected
after redirecting ex vivo to FcγR the Id protein or whole tri-
oma cells, these Id-specific Ab titres never correlated with
tumor protection in vivo. Rather, T cells were instrumental
for tumor eradication.
Our results show that a possible competition between dif-
ferent Ag [15] does not hamper the in vivo effect. Of
course, we cannot preclude a selection of Ag and a bias
T-cell proliferation after priming with DC that were pulsed with the indicated reagents Figure 3
T-cell proliferation after priming with DC that were pulsed with the indicated reagents. DC were unpulsed or 
loaded with the soluble A20 Ig idiotype, with A20 cells, with a soluble heterodimeric A20 Ig idiotype containing the anti-FcR 
binding arm or with BiV cells. For blocking FcR-mediated Ag uptake during coincubation with BiV cells, the anti-FcR mAb 
2.4G2 was added. Proliferation of T cells was determined by 3H-thymidine uptake. Proliferation indices were calculated by nor-
malizing the radioactivity incorporated in T cells to the background levels without T cells. The bars represent results at a T 
cell/DC ratio of 9:1. Mean values and standard deviations are compiled from 3 experiments.
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Eradication of established A20 lymphomas by DC that were pulsed with the indicated reagents Figure 4
Eradication of established A20 lymphomas by DC that were pulsed with the indicated reagents. (a) Effect of load-
ing DC with different formulations of the purified soluble A20 Id. (b) Effect of loading DC with whole unmodified lymphoma 
cells (A20) or with trioma cells (BiV) or with a mixture of A20 cells and purified BiV heterodimeric Ig. The difference between 
the trioma cell-treated group and the control group without therapy was significant with p < 0.05 (logrank test).
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Mechanisms of DC-mediated tumor protection Figure 5
Mechanisms of DC-mediated tumor protection. (a) Humoral anti-Id responses in mice vaccinated with DC that were 
pulsed with the purified A20 Id/anti-FcγR heterodimeric BiV protein or with whole BiV cells. Results were expressed as those 
reciprocal Ab titres that gave two-fold extinction above background. Means were calculated from 6 (BiV protein) and from 12 
mice (BiV cells), respectively. Standard deviations are also indicated. (b) Effect of CD4+ and CD8+ T-cell depletion on survival of 
mice treated with DC that were pulsed with BiV cells. The survival of CD4+ or CD8+ T-cell-depleted mice was not significantly 
different from the tumor control group that did not receive any therapy (logrank test). (c) Survival of tumor-bearing mice that 
were injected with trioma cell-loaded DC from β2m-deficient animals which were or were not matured by LPS following the 
loading step. The therapeutic effect of BiV cell-pulsed mDC from β2m-deficient animals was not significantly different from BiV 
cell-pulsed mDC from normal mice (logrank test). Tumor control groups without therapy are also shown in both survival dia-
grams. Typical results are depicted from two experiments in each setting.
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towards peptides of high affinity, but the peptides that are
presented in the context of MHC molecules and give rise
to T-cell activation seem to be sufficient to induce tumor
eradication.
As malignant lymphoma in humans still has a poor prog-
nosis, new therapeutic modalities are needed. The mouse
model explored in this paper may give hints to the devel-
opment of DC-based immunotherapies of malignant
Non-Hodgkin lymphoma.
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